DK0777679T3 - Indføring af nukleinsyrer - Google Patents

Indføring af nukleinsyrer

Info

Publication number
DK0777679T3
DK0777679T3 DK95927594T DK95927594T DK0777679T3 DK 0777679 T3 DK0777679 T3 DK 0777679T3 DK 95927594 T DK95927594 T DK 95927594T DK 95927594 T DK95927594 T DK 95927594T DK 0777679 T3 DK0777679 T3 DK 0777679T3
Authority
DK
Denmark
Prior art keywords
pct
carbon atoms
acyl group
group derived
fatty acid
Prior art date
Application number
DK95927594T
Other languages
English (en)
Inventor
Robert Whittaker
Fiona Helen Cameron
Veronika Bender
Minoo Moghadham
Philip Anthony Jennings
Original Assignee
Commw Scient Ind Res Org
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commw Scient Ind Res Org filed Critical Commw Scient Ind Res Org
Application granted granted Critical
Publication of DK0777679T3 publication Critical patent/DK0777679T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003Peptide-nucleic acids (PNAs)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK95927594T 1994-08-16 1995-08-16 Indføring af nukleinsyrer DK0777679T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPM7476A AUPM747694A0 (en) 1994-08-16 1994-08-16 Delivery of nucleic acids and peptides
AUPM7677A AUPM767794A0 (en) 1994-08-16 1994-08-25 Delivery of nucleic acids and peptides
PCT/AU1995/000505 WO1996005218A1 (en) 1994-08-16 1995-08-16 Delivery of nucleic acids

Publications (1)

Publication Number Publication Date
DK0777679T3 true DK0777679T3 (da) 2003-12-01

Family

ID=25644738

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95927594T DK0777679T3 (da) 1994-08-16 1995-08-16 Indføring af nukleinsyrer

Country Status (14)

Country Link
US (1) US5906922A (da)
EP (1) EP0777679B1 (da)
JP (1) JP3763577B2 (da)
CN (1) CN1210290C (da)
AT (1) ATE253588T1 (da)
AU (3) AUPM747694A0 (da)
CA (1) CA2197653C (da)
DE (1) DE69532081T2 (da)
DK (1) DK0777679T3 (da)
FI (1) FI970648A7 (da)
NO (1) NO970651L (da)
NZ (1) NZ290757A (da)
RU (1) RU2160278C2 (da)
WO (1) WO1996005218A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) * 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
EP0874910A4 (en) * 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
EP0775751A3 (en) * 1995-11-22 1998-06-10 F. Hoffmann-La Roche Ag Cell transfection
AUPN741696A0 (en) * 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
NZ512244A (en) 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
AU2001260467A1 (en) * 2000-05-30 2001-12-11 Ich Productions Limited Integrin-targeting vectors having enhanced transfection activity
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
CA2469623C (en) * 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
AUPS145602A0 (en) * 2002-03-28 2002-05-09 Commonwealth Scientific And Industrial Research Organisation Composition and method for killing tumours
EP1545432A4 (en) * 2002-09-26 2007-03-14 Pfizer Prod Inc USE OF AUXILIARY SUBSTANCES TO INCREASE DNA RECEPTION BY PIG MUSCLE CELLS
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
EP1938843A1 (en) * 2006-12-19 2008-07-02 Novosom AG Lipids and lipid assemblies comrising transfection enhancer elements
EP1935434A1 (en) * 2006-12-19 2008-06-25 Novosom AG Construction and use of transfection enhancer elements
WO2008074487A2 (en) * 2006-12-19 2008-06-26 Novosom Ag Lipids and lipid assemblies comprising transfection enhancer elements
EP2681326A4 (en) * 2011-02-28 2016-11-09 Politechnic Inst Univ New York PREPARATION OF PEPTIDE MIXTURES BY PROTEASE CATALYSIS FOR THE PRODUCTION OF USEFUL BIOLOGICAL AND PHYSICAL PROPERTIES
US9895005B2 (en) * 2014-05-21 2018-02-20 Kids Ii, Inc. Convertible child seat
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
US12428641B2 (en) 2017-09-15 2025-09-30 Commonwealth Scientific And Industrial Research Organisation RNA molecules
EP4559896A4 (en) * 2022-07-19 2025-10-22 Univ Hokkaido Nat Univ Corp PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE
CN116496193B (zh) * 2023-03-10 2026-01-02 圣诺生物医药技术(苏州)有限公司 一种氨基酸脂质形成的纳米递送系统及其应用
WO2025140190A1 (en) * 2023-12-25 2025-07-03 Microbio (Shanghai) Co., Ltd. Carbon chain-modified nucleic acids and uses thereof for bacterial cell delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
DK0506748T3 (da) * 1989-12-22 1996-01-22 Commw Scient Ind Res Org Aminosyrer, peptider eller derivater deraf bundet til fedtstoffer
SE465221B (sv) * 1989-12-29 1991-08-12 Berol Nobel Ab Saett att kovalent binda proteiner till hydrofila ytor
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JP2958076B2 (ja) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
DE69230855D1 (de) * 1991-07-26 2000-05-04 Commw Scient Ind Res Org System der bereitstellung eines impfstoffes auf peptidbasis, das sein eigenes adjuvans bildet, und seine herstellung
DE69233046T2 (de) * 1991-10-24 2004-03-04 Isis Pharmaceuticals, Inc., Carlsfeld Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CA2131620A1 (en) * 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
US5329029A (en) * 1992-11-05 1994-07-12 Wan Barbara Y Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
CA2160878A1 (en) * 1993-04-19 1994-10-27 Medisorb Technologies International L.P. Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression
CA2167818A1 (en) * 1993-08-02 1995-02-09 Robert George Whittaker Therapeutic compound - fatty acid conjugates

Also Published As

Publication number Publication date
JPH10509862A (ja) 1998-09-29
AUPM747694A0 (en) 1994-09-08
NO970651D0 (no) 1997-02-12
DE69532081D1 (de) 2003-12-11
DE69532081T2 (de) 2004-09-09
WO1996005218A1 (en) 1996-02-22
US5906922A (en) 1999-05-25
CA2197653C (en) 2009-04-28
EP0777679A4 (en) 1997-10-08
CA2197653A1 (en) 1996-02-22
RU2160278C2 (ru) 2000-12-10
FI970648L (fi) 1997-04-07
NZ290757A (en) 2000-09-29
FI970648A0 (fi) 1997-02-14
ATE253588T1 (de) 2003-11-15
NO970651L (no) 1997-04-02
AU3158595A (en) 1996-03-07
CN1210290C (zh) 2005-07-13
EP0777679A1 (en) 1997-06-11
CN1158619A (zh) 1997-09-03
AU684383B2 (en) 1997-12-11
FI970648A7 (fi) 1997-04-07
JP3763577B2 (ja) 2006-04-05
EP0777679B1 (en) 2003-11-05
AUPM767794A0 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
DK0777679T3 (da) Indføring af nukleinsyrer
SE8403931L (sv) Treo-3-amino-2-hydroxi-4-oxosmorsyraderivat
DE69711391D1 (de) Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern
GB9412590D0 (en) Organic compounds
ES2073706T3 (es) Nuevos derivados de acidos fosfono-alcanopolicarboxilicos y sus utilizaciones.
DE69422366D1 (de) Waschmittelzusammensetzung
DE3062609D1 (en) Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds
ES2118564T3 (es) Agente de limpieza para superficies duras.
DE59405810D1 (de) Verfahren zur herstellung von festen esterquats
ES2152563T3 (es) Procedimiento para preparar derivados de dihidroxipirimidina.
NZ502837A (en) Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the DNA polymerase of hepatitis B virus (HBV)
KR840005733A (ko) 무라밀 펩타이드의 제조방법
NO20023276L (no) Fremgangsmåter fremstilling av betulinsyre
MX9605737A (es) Transfeccion de celulas.
DE69633281D1 (de) Etherderivate von pseudopterosin
ATE186737T1 (de) Ein verbessertes verfahren für die herstellung von seitenketten-derivaten von cyclohexapeptidyl- lipopeptiden
ATE184590T1 (de) Verfahren zur herstellung von fettsäureamiden und ihre verwendung
GB2012261A (en) Long-chain fatty acid amides and hydrazides and cyclopropano analogues thereof, their production and their use as anti-atherosclerotic agents
DE69809205D1 (de) Verfahren zur herstellung von azyklischen nukleosiden
EP0331756A4 (en) Agents for prophylaxis and treatment of thrombopenia
GEP19970937B (en) Method of producing derivatives of muramyldipeptide
MX9604924A (es) 2,3-dihidroxipropil-2-(1-oxoalquil)amino-2-desoxiglucopiranosidos, un procedimiento para su preparacion y su uso.